Imaging in haematology, beyond morphology.
In haematological malignancies, imaging is central to response assessment, staging and defining functional minimal residual disease — biological dynamics that demand standardised, quantitative approaches.
Metabolic response, controlled for variability.
In conditions such as lymphomas and multiple myeloma, PET/CT is a key tool for initial staging, assessing metabolic response and identifying residual disease.
Applying criteria such as Deauville or other metabolic scoring systems requires rigorous reviewer calibration and careful control of interpretative variability — small differences in uptake assessment can alter response classification.
We implement structured reviewer training, review consistency, independent adjudication and multicentre technical harmonisation — ensuring consistency in assessments and greater statistical robustness.
See our approach
Methodological control for complex biology.
Haematological response is read on metabolic signal, not just size. We align reviewers, sequence reviews and harmonise sites so Deauville and quantitative reads stay consistent and statistically robust.
- Structured reviewer training. Reviewers aligned to Deauville and study-specific scoring.
- Review consistency. Standardised reads that hold across timepoints and centres.
- Independent adjudication. Controlled resolution of discrepant response classifications.
- Multicentre harmonisation. Technical alignment of PET/CT across platforms and sites.
- Statistical robustness. Lower interpretative variability strengthens the analysis.
Illustrative interface — sample data, not client results.
Precision medicine needs reproducible reads.
New cell-based and immunotherapy treatments demand sophisticated assessment. Functional imaging monitors early response and supports adaptive strategies — only when quantitative parameters are standardised across centres.
Early response
Functional signal that surfaces treatment response ahead of structural change.
True vs pseudo-progression
Distinguishing genuine progression from inflammatory phenomena under immunotherapy.
Adaptive strategies
Imaging read-outs that inform response-adapted treatment decisions.
Quantitative standardisation
Reproducible parameters that hold across reviewers and acquisition sites.
Algorithmic harmonisation
Site qualification and harmonisation that reduce technical variability before it reaches interpretation.
Dosimetry for radiolabelled therapies.
We work with medical physicists and clinical centres to ensure accurate dosimetric modelling consistent with the study’s clinical objectives.
The expansion of radiolabelled therapies in haematology makes the integration of imaging and dosimetry a key element of development.
Accurate quantification of the absorbed dose enables therapy to be optimised, risk to be better managed and robust regulatory documentation to be provided.
Haematological studies are also methodologically demanding — composite endpoints, imaging combined with laboratory biomarkers, small populations and significant regulatory scrutiny. We protect data quality through a structured imaging charter, continuous quality control, compliant and traceable archiving, and support in the event of a regulatory audit.
Imaging governance as a factor for success.
In haematology, imaging is not merely diagnostic — it is integral to response assessment and treatment strategy.
-
Technically harmonised
PET/CT aligned across platforms and centres for comparable reads.
-
Methodologically controlled
Charter, calibration and review governing every assessment.
-
Statistically robust
Reduced variability that supports cleaner composite endpoints.
-
Regulatorily defensible
Traceable, compliant data that holds up under audit.
Lymphoma and myeloma trials, published.
Haematology trials supported by WIDEN, and the imaging methodology published from them. See all publications.
- Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study (opens in a new tab)
- Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi (opens in a new tab)
- Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial (opens in a new tab)
- PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort (opens in a new tab)
- End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial (opens in a new tab)
- Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results (opens in a new tab)
- Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) (opens in a new tab)
- Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study (opens in a new tab)
- Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) (opens in a new tab)
Strengthen the imaging behind your haematology study.
Discover how harmonised, independently governed imaging can protect the scientific integrity of your haematology trial.